BioNTech grabs PD-L1/VEGF bispecific with $55M upfront, expanding pipeline while lowering Covid guidance

Kyle LaHucik

Senior Reporter

As BioNTech continues to beef up its oncology pipeline, it’s once again turning to a Chinese partner.

The German biotech is putting down $55 million upfront for a collaboration deal with Biotheus, which is based out of Zhuhai, China. In return, BioNTech will get a global ex-China license of PM8002, a bispecific simultaneously targeting PD-L1 and VEGF now being tested in Phase II studies in China, the companies said Monday morning. BioNTech returned to the region after striking two antibody-drug conjugate pacts earlier this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

BioNTech grabs PD-L1/VEGF bispecific with $55M upfront, expanding pipeline while lowering Covid guidance

Amber Tong

Senior Editor

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

Pfizer sticks to the script in first-quarter update as cost cuts are 'largely complete'

Boehringer puts a target on Humira, says pushing it off formularies is necessary

GSK expedites Blenrep timelines as it eyes second chance in multiple myeloma

Is UnitedHealth Group too big? Senators grill CEO on key question in wake of cyberattack

Pfizer makes small pipeline changes in first-quarter update

A New Precision Approach for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

BioN­Tech grabs PD-L1/VEGF bis­pe­cif­ic with $55M up­front, ex­pand­ing pipeline while low­er­ing Covid guid­ance

Senior Editor

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

BioNTech grabs PD-L1/VEGF bispecific with $55M upfront, expanding pipeline while lowering Covid guidance